Use este identificador para citar ou linkar para este item:
http://sgc.anlis.gob.ar/handle/123456789/2116
Título: | Estabilidad de la vacuna Candid#1 para prevenir la fiebre hemorrágica Argentina | Outros títulos: | Stability of Candid#1 vaccine to prevent Argentine Hemorrhagic Fever | Autor(es): | Saavedra, María del Carmen Riera, Laura M Bottale, Alejandro J Mariani, Mauricio A Maiza, Andrea Ambrosio, Ana María |
Palavras-chave: | Potencia de la Vacuna;Virus Junin | Data do documento: | 2017 | Jornal: | Medicina (Buenos Aires) | Resumo: | Candid#1 is the first live attenuated vaccine produced and registered in Argentina. Produced since 2003 at the INEVH to prevent Argentine hemorrhagic fever, it is obtained by harvesting supernatants of diploid cells infected with an attenuated strain of Junin virus and subsequent lyophilization. The stability of this vaccine is crucial to ensure its effectiveness. This study was aimed to evaluate the stability of Candid#1 by exposing it to different time and temperature conditions. Three vaccine batches produced in 2003 were analysed according to the following storage scheme: (a) reconstituted vaccine at 2 °C to 8 °C for 8 days; (b) lyophilized vaccine at 2 °C to 8 °C for 6 months; (c) lyophilized vaccine at -18 °C to -20 °C for 10 years. The potency was assessed in Vero cell monolayers under agar. The results were: (a) reconstituted vaccine was stable between 2 °C and 8 °C for 8 days, (b) lyophilized vaccine was stable between 2 °C and 8 °C for 2 months, and (c) lyophilized vaccine was stable 9 years between -18 °C and -20 °C, keeping all its properties. These results allowed us to establish the following storage conditions and expiration times for Candid#1: (a) reconstituted: 12 hours between 2 °C and 8 °C, (b) lyophilized: 30 days between 2 °C and 8 °C and (c) lyophilized: 9 years between -18 °C and -20 °C. Based on our results, favorable changes were made in the conditions of transport, storage and distribution of the vaccine. Domestic freezers in strategically located centers were installed, allowing the preservation of vaccine stocks for distribution to secondary vaccination centers. |
Descrição: | Fil: Saavedra, María Del Carmen. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina. Fil: Riera, Laura M. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina. Fil: Bottale, Alejandro J. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina. Fil: Mariani, Mauricio A. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina. Fil: Maiza, Andrea S. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina. Fil: Ambrosio, Ana María. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina. |
URI: | http://www.medicinabuenosaires.com/PMID/29044009.pdf http://sgc.anlis.gob.ar/handle/123456789/2116 |
ISSN: | 0025-7680 | Direitos: | Open Access Creative Commons Attribution 4.0 International License |
Aparece nas Coleções: | Publicaciones INEVH |
Arquivos neste item:
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
MEDICINA_Buenos Aires_2017_77_353-357.pdf | Artículo en español | 374.68 kB | Adobe PDF | Ver/Aberto |
Visualização de página
17
Checado em 03/05/2024
Download(s)
2
Checado em 03/05/2024
Google ScholarTM
Checar
Este item está licenciada sob uma Licença Creative Commons